Vir Biotechnology, Inc. VIR
Vir Biotechnology, Inc. (Nasdaq: VIR) is an oncology drug developer. Its lead program, VIR-5500/ASP6958, is in Phase 1 for metastatic castration-resistant prostate cancer (mCRPC). Its next catalyst on record is Elebsiran and tobevibart combination: Presentation of expanded Phase 2 SOLSTICE results at AASLD (November 2026).
Upcoming catalysts
- November 2026Elebsiran and tobevibart combination — Presentation of expanded Phase 2 SOLSTICE results at AASLD
We will present expanded Phase 2 SOLSTICE results in oral presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 on November 8.
Next further out: Elebsiran and tobevibart combination — Topline data from pivotal ECLIPSE 1 trial (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Elebsiran and tobevibart combination | chronic hepatitis delta (CHD) | oligonucleotide-other | Phase 3 |
| VIR-5500/ASP6958 | metastatic castration-resistant prostate cancer (mCRPC) | biologic-other | Phase 1 |
| VIR-5818 | HER2-expressing tumors | biologic-other | Phase 1 |
| VIR-5525 | EGFR-expressing tumors | biologic-other | Phase 1 |
Recent results and decisions
- Nov 4, 2026n/a U.S. FDA granted Fast Track designation to VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer.
U.S. FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC).
Filing - Nov 4, 2026positive VIR-5500 achieved proof of concept in Phase 1 trial.
VIR-5500 has achieved proof of concept, reinforcing the scientific rationale for advancing the program into late-stage development.
Filing - Aug 5, 2026completed enrollment ECLIPSE 2 Phase 3 completed enrollment; entire ECLIPSE program now fully enrolled.
The Company completed enrollment in the Phase 3 ECLIPSE 2 trial, and the entire ECLIPSE registrational program is now fully enrolled.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
- Adlai Nortye Group Ltd. ANL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.